Clinical Trial Update: Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dual EGFR inhibition with erlotinib and panitumumab, with or without chemotherapy, in advanced colorectal cancer; results posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Panitumumab (panitumumab)

Snippet

Sponsor: Northwestern University | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-05-07